What's Happening?
The Medicare Drug Price Negotiation Program (MDPNP), established under the Inflation Reduction Act of 2022, has begun negotiating prices for high-cost prescription drugs. The first ten negotiated drugs, which took effect on January 1, 2026, represent
discounts ranging from 38% to 79% off previous prices, covering drugs that accounted for $56.2 billion in Medicare Part D spending. The Centers for Medicare and Medicaid Services (CMS) projects first-year savings of approximately $6 billion for the program and $1.5 billion in out-of-pocket savings for 8.8 million Part D enrollees. However, the implementation of the Maximum Fair Price (MFP) has created significant cash flow risks for pharmacies. Manufacturers are responsible for ensuring the MFP is available, either by selling drugs at the MFP directly or by providing retrospective refunds. This retrospective refund model means pharmacies often dispense drugs at existing prices and then wait for manufacturer refunds, leading to cash flow gaps. A January 2025 analysis by 3 Axis Advisors, commissioned by the NCPA, found that the MDPNP could result in a weekly cash flow shortfall of $10,838.25 for the average pharmacy.
Why It's Important?
The MDPNP represents a fundamental shift in how prescription drug prices are determined in the U.S., aiming to reduce healthcare costs for Medicare beneficiaries. While patients benefit from lower out-of-pocket expenses, the program's operational mechanics pose substantial financial challenges for pharmacies. The cash flow gaps created by the retrospective refund model could jeopardize the financial stability of many pharmacies, particularly smaller, independent ones. This financial strain could lead pharmacies to consider not stocking negotiated drugs, as indicated by a survey where 93.2% of pharmacies were considering or had already chosen not to stock one or more of the first ten negotiated drugs. Such actions could severely impact patient access to essential medications, especially in rural areas and pharmacy deserts, undermining the program's goal of affordability and access. The uncertainty surrounding Part D plan reimbursement rates further exacerbates the issue, as pharmacies worry that plans may not adjust their rates to reflect the MFP, leaving pharmacies to absorb the difference while awaiting manufacturer refunds.
What's Next?
The MDPNP is set to expand, with 15 more drugs selected for negotiation in 2027, including Part B drugs administered in physician offices and infusion settings, and 20 additional drugs annually thereafter. Final prices for the 2027 round are expected by August 2026. Pharmacies will need to actively monitor CMS guidance and the Medicare Transaction Facilitator (MTF), which manages MFP refunds, to understand and mitigate cash flow impacts. They are also advised to maintain meticulous dispensing and reimbursement records for audit purposes and engage with pharmacy associations like the NCPA, which are advocating for pharmacy protections within the MDPNP framework. The ongoing expansion of the program means pharmacies will require continuous financial planning and operational adaptation. The potential for pharmacies to limit stocking of negotiated drugs could prompt further discussions and adjustments to the program's implementation to ensure patient access and pharmacy viability.
Beyond the Headlines
The MDPNP highlights a broader tension between government efforts to control healthcare costs and the operational realities of the healthcare supply chain. While the program aims to address the ethical concern of high drug prices and improve affordability for seniors, its current implementation inadvertently shifts financial burdens onto pharmacies, which are critical access points for medication. This situation could lead to unintended consequences, such as consolidation within the pharmacy sector or a decline in independent pharmacies, further impacting community health infrastructure. The debate also touches upon the long-standing issue of transparency in drug pricing and reimbursement, as pharmacies seek clearer guidelines for how Part D plans will integrate negotiated prices. The success of the MDPNP in achieving its long-term goals will depend not only on the discounts secured but also on the ability of all stakeholders, including CMS, manufacturers, and pharmacies, to establish a sustainable and equitable operational framework.
